FDA Approves Medtronic’s Onyx Frontier Drug-Eluting Stent

Bibliometric Details: Issue No: 5 | Issue Month:May | Issue Year:2022

The US Meals and Drug Administration (FDA) has accredited the Onyx Frontier drug-eluting stent (DES) to address sufferers with coronary artery illness, the instrument producer, Medtronic, announced these days.

The Onyx Frontier shares the identical stent platform and scientific indications as the outdated period Resolute Onyx zotarolimus-eluting stent, including the most up-to-date acclaim for sufferers at excessive probability of bleeding who could presumably well make a selection pleasure in appropriate 1 month twin-antiplatelet therapy.

“Considerable manufacture adjustments, including elevated catheter flexibility, an revolutionary twin-layer balloon technology and a lower crossing profile led to a 16% enchancment in deliverability with Onyx Frontier vs the outdated period Resolute Onyx DES,” Medtronic mentioned in a news free up.

Onyx Frontier also presents a huge dimension matrix to address extra sufferers, and joins the Resolute Onyx as the finest 2.0 mm DES obtainable in the US, the firm noted. The stent is equipped in 4.5 to 5.0 mm sizes that will also be expanded to 6.00 mm, particularly designed to crimson meat up extra-trim vessels.

The Onyx Frontier DES is pending CE Mark in Europe.

Notice Patrice Wendling on Twitter: @pwendl For extra from | Medscape Cardiology, notice us on Twitter and Facebook.

Content Protection by

Back to top button